CSL312 (Garadacimab) in the Prevention of Hereditary Angioedema Attacks

Clinical trial NCT04656418 · COMPLETED

Trial details

NCT number: NCT04656418
Sponsor: CSL Behring
Status: COMPLETED
Phase: Phase 3
Study type: INTERVENTIONAL

Hereditary Angioedema

Start date: 2021-01-27
Primary completion: 2022-06-07
Enrollment: 64

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.